Engineered MSCs from Patient-Specific iPS Cells
Engineered MSCs from Patient-Specific iPS Cells
复制标题
DOI：
10.1007/10_2012_156
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Cantz, Tobias
中科院分区：
文献类型：
--
作者：
Eberle, Irina;Moslem, Mohsen;Cantz, Tobias
间充质基质/干细胞（MSC）代表可以从身体的各种组织分离或可以通过体外分化由多能干细胞产生的异源细胞群体。各种有前景的临床前和临床研究表明，MSC可能刺激内源性再生和/或充当抗炎剂，这可能对许多疾病具有高度治疗相关性，包括同种异体造血干细胞移植后的移植物抗宿主病、炎症性肠病或某些形式的肝功能衰竭。值得注意的是，各种研究的相互矛盾的结果表明，MSC的来源，培养条件和给药方式对所需的临床效果有重要影响。最近已经阐明了一些涉及的分子途径，并且通过工程化MSC对这些途径进行人工调节可能导致超功能MSC用于增强内源性再生或抗炎反应。在这篇综述中，我们总结了传统的MSC在胃肠病学中的应用的重要发现，我们描述了最先进的患者来源的iPS细胞，最终可能提供基因工程的超功能iPS细胞先进的细胞疗法的产生。
Mesenchymal stroma/stem cells (MSCs) represent a heterogenic cell population that can be isolated from various tissues of the body or can be generated from pluripotent stem cells by in vitro differentiation. Various promising pre-clinical and clinical studies suggest that MSCs might stimulate endogenous regeneration and/or act as anti-inflammatory agents, which could be of high therapeutic relevance for a number of diseases, including graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, inflammatory bowel diseases, or some forms of liver failure. Notably, conflicting results of various studies illustrated that the source of MSCs, the cultivation condition, and the way of administration have important effects on the desired clinical effect. Some of the involved molecular pathways have recently been elucidated and an artificial modulation of these pathways by engineered MSCs might result in superfunctional MSCs for enhanced endogenous regeneration or anti-inflammatory response. In this review, we summarize important findings of conventional MSCs for applications in gastroenterology and we describe the state-of-the-art for the generation of patient-derived iPS cells that eventually might provide genetically engineered superfunctional iPS cells for advanced cell therapies.